Endo to Stop AMS Mesh Production

Endo International PLC disclosed it is officially closing its women’s health division and stopping the manufacture and sale of transvaginal mesh products. Endo disclosed this after release of its quarterly results on Monday, stating that it will close down the mesh line purchased from American Medical Systems (AMS) by March 31, 2016. Endo failed to find a buyer for the product line (now known as Astora Women’s Health).

Levin Simes attorneys co-led the national litigation against AMS. In addition to securing substantial compensation for the clients of Levin Simes, our attorneys helped settle approximately 20,000 AMS vaginal mesh-related claims of other law firms in May 2014. Levin Simes continues to represent those injured by transvaginal mesh products.

In August 2015, Endo stated that it would set aside $1.53 billion to help settle the lawsuits of women regarding the faulty mesh devices. The use of transvaginal mesh for treatment of pelvic organ prolapse (POP) and stress urinary incontinence (SUI) has resulted in thousands of lawsuits for design failures and failure to warn of risks. Levin Simes LLP has successfully settled AMS cases on behalf of its clients and clients around the country, and attorneys at Levin Simes have acted as lead counsel in the litigation.

The FDA stated it would change regulation regarding the approval of these devices due to the failures and injuries as well as label the devices as high risk.

News and Links:

• Wall Street Journal: Endo International to Close Astora Women’s Health Due to Lawsuit Concerns
• FDA: FDA strengthens requirements for surgical mesh for transvaginal repair of pelvic organ prolapse
• Levin Simes: Levin Simes help settle 20,000 AMS cases